CryptoPS screening – preventing cryptococcal infection in clinical practice
With BIOSYNEX CryptoPS, it becomes possible to identify high-risk patients with latent or active Cryptococcus sp. infection. This rapid test is an effective screening tool for preventing cryptococcal meningitis – a deadly infection, especially among HIV-positive people with low CD4 counts.
CryptoPS enables proactive screening
The test is recommended for patients with a CD4 level below 200 cells/µL and can be used directly in the clinic. CryptoPS delivers results in 10 minutes and requires only a small amount of blood or CSF. The T2 line serves as an indicator of a high antigen level and possible severe infection.
Better treatment through early detection
With early use of CryptoPS, antifungal treatment can be initiated quickly, before meningitis develops. The test is suitable for use in HIV clinics, infectious disease departments and resource-limited settings.
Supports international guidelines
CryptoPS has been validated in WHO-recommended programs and clinical studies in, among other places, Africa and Asia. It is already used in national screening initiatives and contributes to significantly lower mortality from opportunistic infections. See also our health tests and infection marker categories.
FAQ – CryptoPS screening and clinical use
Who should be screened with CryptoPS?
HIV patients with low CD4 counts, organ transplant recipients and other immunocompromised patients.
Can the test be integrated into routine programs?
Yes. CryptoPS is suitable for both routine screening and acute assessment, and it does not require advanced equipment.
How are the results interpreted?
A positive T1 indicates the presence of Cryptococcus antigen. T2 indicates a high concentration and should lead to further investigation and treatment.
